Table 3.
Patients with DSAs against both UCB units
| UPN (N=6) | Unit | CD34 (×106/kg) | Anti-HLA Antibody Specificity for UCB Unit | MFI | Chimerism at Day +21 (%) | Long-Term Predominant Unit | Days to neutrophil recovery* | Outcome |
|---|---|---|---|---|---|---|---|---|
| 4591 | 1 | 0.44 | A23 (A*23); Cw16 (Cw*16) | 9853; 889 | 0 | NA | 25 | Engrafted; Early Relapse |
| 2 | 0.13 | Cw5 (Cw*05); DR1 (DRB1*01); DQ5 (DQB1*05) | 3797; 14177; 13618 | 47 | NA | |||
|
| ||||||||
| 4626 | 1 | 0.28 | A1 (A*01) | 2644 | 0 | no | 24 | Engrafted |
| 2 | 0.27 | B44 (B*44) | 5417 | 99 | yes | |||
|
| ||||||||
| 4693 | 1 | 0.46 | B60 (B*40:01); Cw7 (Cw*07) | 3176; 12354 | 95 | NA | NA | Graft failure |
| 2 | 0.49 | B51 (B*51); Cw15 (Cw*15); DR4 (DRB1*04) | 2130; 519; 19112 | 0 | NA | |||
|
| ||||||||
| 4777 | 1 | 0.18 | A2 (A*02) | 646 | 100 | yes | 9 | Engrafted |
| 2 | 0.19 | A2 (A*02) | 646 | 0 | no | |||
|
| ||||||||
| 4547 | 1 | 0.42 | DR4 (DRB1*04:01) | 660 | 31 | yes | 32 | Engrafted |
| 2 | 0.31 | DR4 (DRB1*04:01) | 660 | 69 | no | |||
|
| ||||||||
| 4479 | 1 | 0.27 | A3 (A*03); Cw3 (Cw*03) | 6377; 1104 | 49 | yes | 24 | Engrafted |
| 2 | 0.11 | A3 (A*03); Cw3 (Cw*03) | 6377; 1474 | 51 | no | |||
*
> 500/mcL.
Abbr: DSAs, donor specific antibodies; UPN, unique patient number; HLA, human leukocyte antigen; UCB, umbilical cord blood; MFI, mean fluorescence intensity; NA, not applicable or not available or not achieved.